Implementation of the Guideline on Pharmaceutical Care and Selection of Magnesium, Riboflavin and Coenzyme Q10 for Prevention of Migraines Relapses in Community Pharmacies
Article Sidebar
Main Article Content
Abstract
Objectives: To develop the guideline for counseling and selecting dietary supplements (DS) containing magnesium, riboflavin, or coenzyme Q10 to prevent migraine relapses (Guideline), evaluate community pharmacists' satisfaction with the Guideline and employ it for assessing forms and dosages of the DS sold in pharmacies. Method: The researchers searched primary literature for developing the Guidelines. The study assessed satisfaction with the Guidelines after one-month implementation among 94 pharmacists in community pharmacies in Mueang District, Pathum Thani Province, respectively. The researcher used the Guidelines to assess48DSs sold in pharmacies on the aspects of forms and dosages. Results: The Guidelines included results of the literature review on efficacy and safety of using magnesium, riboflavin, or coenzyme Q10 in preventing migraine recurrence and guidelines for product selection. Pharmacists were satisfied with the complete version of the Guidelines at a high level (average score 4.2±0.7 out of 5). Satisfaction in understanding the content and application, format of the guidelines and the overall aspect of the guidelines had scores of 4.2±0.7, 4.1±0.7 and 4.3±0.7 out of 5, respectively. Four out of 48 products (8.3%) had ingredients and dosages consistent to empirical evidence. Conclusions: Contents of the developed Guidelines were useful in recommending products to prevent migraines relapse. A few products available in pharmacies in Mueang District, Pathum Thani had ingredients and dosages consistent to empirical evidences.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954-76.
Phanthumchinda K, Kamol-Ratanakul P. Prevalence of primary headache in central region of Thailand: a cross-sectional survey. J Neurol 1999; 246suppl 1: S319.
Phanthumchinda K, Sithi-Amorn C. Prevalence and clinical features of migraine: a community survey in Bangkok, Thailand. Headache 1989; 29: 594-7.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9
Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. Headache 2019; 20: 41.
Blumenfeld A, Varon S, Wilcox T, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31: 301-15.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-59.
Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019; 18: 891-902.
Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 2015; 55: 103-22.
Puledda F, Shields K. Non-pharmacological approaches for migraine. Neurotherapeutics 2018; 15: 336-45.
Chaibi A, Tuchin P, Russell MB. Manual therapies for migraine: a systematic review. Headache 2011; 12: 127-33.
Luedtke K, Allers A, Schulte LH, May A. Efficacy of intervention used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis. Cephalalgia 2016; 36: 474-92.
Dinner HC, Krenfeld K, Boewing G, Lungenhausen M, Maier C, Molsberger A, et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicenter randomized controlled trial. Lancet Neurol 2006; 5: 310-6.
Xu J, Zhang FQ, Pei J, Ji J. Acupuncture for migraine without aura: a systematic review and meta-analysis. J Integr Med 2018; 16: 312-21.
Okoli GN, Rabbani R, KashaniHH, Wierzbowski AK, Neilson C, Mansouri B, et al. Vitamins and minerals for migraine prophylaxis: a systematic review. Can J Neurol Sci 2019; 46: 224-33.
Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002; 22: 209-21.
Sadeghian H, Motiei-Langroundi R. Comparison of levetiracetam and sodium valproate in migraine prophylaxis: a randomized placebo-controlled study. Ann Indian Acad Neurol 2015; 18: 45-8.
Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention. Arch Neurol 2004; 61: 490-5.
Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 2016; 87: 741-49.
Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, et al. Migraine and sleep disorders: a systematic review. Headache 2020; 21: 126.
Nye BL, Thadani VM. Migraine and epilepsy: review of the literature. Headache 2015; 55: 359-80.
Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1152407 subjects. BMJ Open 2018; 8: e020498.
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis a randomized controlled trial. Neurology 1998; 50: 466-70.
TarighatEsfanjani A, Mahdavi R, Ebrahimi Mame- ghani M, Talebi M, Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res 2012; 150: 42–8.
Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-63.
Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64: 713-5.
Takahashi M, Uchino N. Risk factors of hypermag- nesemia in end-stage cancer patients hospitalized in a palliative care unit. Ann Palliat Med 2020; 9: 4308-14.
Saengcharoen W, Buasri N, Khantapokha B, Lerkiatbundit S. Public knowledge and factors associated with inappropriate analgesic use: a survey in Thailand. Int J Pharm Pract 2016; 24: 22-9.
Korsanan S. Form and capacity of pharmacists in their responsibilities in pharmacies that are certified for high quality medicines. Journal of Human Resource Intelligence 2012; 7: 47-52.
Sangkar P, Hongsamoot D. Practice interest and readiness of community pharmacists toward communitypharmacists’ role development. Journal of Health Science of Thailand 2010; 19: 982-95.
BuanuiN.Readiness of drug store operators in Public Health Inspection Area 7 to comply with drug store standard criteria in the drug store quality develop- ment and certification project [master thesis]. Bangkok: Sukhothai Thammathirat; 2009.
Hoffmann W, Herzog B, Muhlig S, Kayser H, Fabian R, Thomsen M, et al. Pharmaceutical care for migraine and headache patients: a community-based randomized intervention. Ann Pharmacother 2008; 42: 1804-13.
OTC Products: A study of pharmacists' recommen- dations. Pharm Times 2001; 67: 10-30.
The Neurological Society of Thailand. Thai Headache Society Guideline for medical practice diagnosis and treatment migraine headache. Bangkok: Thanapress; 2022.
Sripairoj N. Basic research principles. Bangkok: Suksaporn; 1984.
Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician 2019; 99: 17-24.
Nattagh-Eshtivani E, Sani MA, Dahri M, Ghalichi F, Ghavami A, Arjang P, Tarighat-Esfanjani A. The role of nutrients in the pathogenesis and treatment of migraine headaches: review. Biomed Pharmaco- ther 2018; 102: 317-25.
Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society Guideline for Migraine Prophylaxis. Can J Neurol Sci 2012; 39 Suppl2: S1-59.
Köseoglu E, Talaslioglu A, SaffetGönül A, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnesium Res 2008; 21: 101-8.
Pfaffenrath V, Wessely P, Meyer C. Magnesium in the prophylaxis of migraine-a double-blind placebo-controlled study. Cephalalgia 1996; 16: 436–40.
Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14: 328-29.
Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the Intensity dependence of auditory evoked cortical potentials. Headache 2000; 40: 30–5.
Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl K, Arnold G. High‐dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11: 475-7.
Nambiar NJ, Aiyappa C, Srinivasa R. Oral riboflavin versus oral propranolol in migraine prophylaxis: an open label randomized controlled trial. Neurol Asia 2011; 16: 223-9.
Athaillah YD, Saing JH, Saing HB, Lelo A. Riboflavin as migraine prophylaxis in adolescents. PaediatrIndones2012; 52: 132-7.
Rahimdel A, Zeinali A, Yazdian-anari P, Hajizadeh R, Arefnia E. Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. Electron Phys 2015; 7: 1344-8.
MICROMEDEX® [Database on the internet]. Colorado: Thomson Reuters (Healthcare); c1973-2024. Toxicology, Riboflavin; [cited 2021 Apr 23]. Available from: www.micromedexsolution.com (Subscription required to view)
Food and Nutrition Board, Institute of Medicine. Dietary reference intakes: thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press: 2000.
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 137–41.
Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011; 31: 897–905.
Shoeibi A, Olfati N, SoltaniSabi M, Salehi M, Mali S, Akbari Oryani M. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg2017; 117: 103-9.
Gaul C, Diener HC, Danesch U, Migravent® Study Group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. Headache 2015; 16: 516.
Hajihashemi P, Askari G, Khorvash F, Reza Maracy M, Nourian M. The effects of concurrent coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Cephalalgia 2019; 39: 648-54.
Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990; 30: 596-608.
Fred DD, Richard PB, Paul RW. User acceptance of computer technology: a comparison of two theoretical models. Manag Sci 1989; 35: 982-1003.
Aungst TD, Miranda AC, Serag-Bolos ES. How mobile devices are changing pharmacy practice. Am J Health Syst Pharm 2015; 72: 494-500.
Wenzel RG, Lipton RB, Diamond ML, Cady R. Migraine therapy: a survey of pharmacists' knowledge, attitudes, and practice patterns. Headache 2005; 45: 47-52.
Lanteri-Minet M, Nachit-Ouinekh F, Mihout B, Slama A, El Hasnaoui A. The treatment of migraine by pharmacists: a French multicenter study. Rev Neurol 2004; 160: 441-6.
Kaur M, Sharma N. Electronic service quality and customer satisfaction: A study of customer loyalty with special reference to tourism industry. Amity Business Rev 2015; 16: 100-14.
Chokjaroenrat O. Assessment of oral contraceptive flowchart using in community pharmacy: Case studies at community pharmacies in Phasi Charoen, Bangkok [master thesis]. Pitsanuloke: Naresuan University; 2016.
Tantisoponwanish N, Polnok A. Development of a common gynecological disease history elicitation instrument for Myanmar workers to be implemented at drug stores. Journal of Community Development and Life Quality 2017; 5: 575-85.
Konghorm N, Thananitisak C. Test of the tool for preventing and managing drug interaction involving HMG-CoA reductase inhibitor within pharmacies. Thai Journal of Pharmacy Practice2019; 11: 378-86.
Lueangaram S. Development of Burmese language history taking manual in common gastro-intestinal disease in drugstores [master thesis]. Pitsanuloke: Naresuan University; 2018.
